Newly Established Samsung Epis Holdings to Drive Growth for Samsung Bioepis and a New Subsidiary
Samsung Epis Holdings to be listed on Korea Exchange (KRX) on November 24, 2025
Samsung Epis Holdings to focus on exploring next-generation growth drivers and optimizing business strategies for its subsidiaries ‒Samsung Bioepis and a new company under Samsung Epis Holdings
Samsung Bioepis will continue to operate its biosimilar business as a 100% owned subsidiary of Samsung Epis Holdings while the new subsidiary company under Samsung Epis Holdings will focus on developing next-generation biotechnology platforms
Kyung-Ah Kim will serve as the President and Chief Executive Officer (CEO) of Samsung Epis Holdings, in addition to her current role as the President and CEO of Samsung Bioepis.
Samsung Epis Holdings Co., Ltd.
As an investment holdings company dedicated to biopharmaceuticals and biotechnology, Samsung Epis Holdings will optimize business strategies for its subsidiaries and maximize corporate and shareholder value through proactive R&D and investment. Samsung Epis Holdings will implement and deploy a focused growth strategy designed to ensure efficient and effective resources while reinforcing the business strategies and platforms for the two subsidiaries.
The New Subsidiary Company
The new subsidiary company under Samsung Epis Holdings will develop next-generation biotechnology platforms targeting various modalities to identify future growth engines beyond the biosimilar business and drive innovation. The new subsidiary will focus on transforming highly scalable core technologies into platforms and discovering diverse new drug candidates, including joint development with global pharmaceutical companies.
For more information about Samsung Epis Holdings and its new subsidiary, please visit: https://www.samsungepisholdings.com/en/
Samsung Bioepis Co., Ltd.
Samsung Bioepis will continue to focus on its core business, including research and development, manufacturing, supply distribution, and commercialization of biologic medicines. Since its foundation in 2012, Samsung Bioepis has developed the industry’s most rapidly advancing biosimilar medicines portfolio, with 11 biosimilars approved and available around the world. In 2024, the company achieved record-breaking sales of KRW 1.5377 trillion and operating profit of KRW 435.4 billion. Samsung Bioepis will focus on strengthening its development capabilities, with a goal of securing 20+ biosimilars in the long-term. Samsung Bioepis has already opened up access to biologic medicines across immunology, oncology, ophthalmology, hematology, and nephrology, and the company is expanding into other therapeutic areas to address unmet needs of patients. For more information about Samsung Bioepis, please visit: www.samsungbioepis.com and follow Samsung Bioepis on social media - LinkedIn, X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251030908044/en/
Website: https://www.samsungepisholdings.com/en/
Contact
Samsung Epis Holdings Co., Ltd.
Anna Nayun Kim
nayun86.kim@samsung.com
Yoon Kim
yoon1.kim@samsung.com
This news is a press release provided by Samsung Epis Holdings Co., Ltd..